% | $
Quotes you view appear here for quick access.

ONYX Pharmaceuticals, AŞ Message Board

  • mcj96 mcj96 Aug 7, 2013 1:22 PM Flag

    $130/sh..........that's it

    What to do with some of your profits ? Buy...... S V N T.......Why? First, SVNT sells for less than 1x 2014 rev estimates and is in the process of aligning its lead orphan therapy's price to a rare disease market. Right now SVNT's Krystexxa is priced at only $5,390/dose vs $34,000/dose for Acthar.......Dr Meeker-the CEO of GENZ-the largest orphan drug co in the world.... joined SVNT's bd this yr. Dr Meeker is ONLY.....on the bd at SVNT according to GENZ's website. Dr Meeker was brought on board to help SVNT better align Krystexxa's price with its smaller, rare disease mkt and better position it for either a sale or partnership. QCOR was in the exct same position as SVNT in early 2007 when it too was.....ugly, unloved, under $1/sh and about to reprice Acthar to rare disease drug levels. The rest is history. QCOR then went from .70/sh in 2007 to $70 /sh after properly aligning Acthar's price and expanding its label. SVNT is in the process of doing the same. Once SVNT initiates another major price raise to $10,000 or there abouts, SVNT will be profitable next yr and have about $125 mil in revs. SVNT will then trade at 4-5x sales.......That's the SVNT trade in a nut-shell. Congratulations again to every old ONXX long who held through thick and thin.

    SortNewest  |  Oldest  |  Most Replied Expand all replies